DailyIQ
Last updated1 minute ago

ISRG·Intuitive Surgical, Inc.

$420.22
-1.84 (-0.44%)
Overnight$418.82-1.40 (-0.33%)
High
$425.50
Open
$425.17
Market Cap
149.88B
52W High
$603.88
Low
$414.65
P. Close
$420.22
P/E
47.75
52W Low
$328.57
Fwd P/E
34.71
DailyIQ Est.
$508.68
Inst. Ownership
42.3%
Short Interest
2.08%
Days to Cover
3.1
Technical Score (1D)
19
BEARISH
News Sentiment
65
BULLISH
On Oct 13, analysts upgraded Intuitive Surgical’s earnings outlook, citing higher estimates, a strong recent quarter, and progress on gastrointestinal robotics projects in early regulatory review. The same day, the company filed a 510(k) for a next‑generation flexible robotic endoscope aimed at gastrointestinal care, noting that the device builds on lessons from its da Vinci and Ion platforms and that revenue impact is not expected until a later stage of development. Also on Oct 13, Zacks Research raised Intuitive Surgical to a Rank #2 (Buy), reflecting the upward revision of earnings estimates and signaling confidence in the company’s future profitability. The earnings outlook upgrade drew renewed investor attention, contributing to a 15.8% rise in the share price over the month following the revision. The GI‑focused endoscope filing was presented as a strategic expansion beyond traditional soft‑tissue surgery, while the Zacks upgrade was expected to support near‑term stock price movement. Together, these developments highlighted analysts’ optimism about Intuitive Surgical’s growth prospects and its evolving product portfolio.
LOW TARGET
$324 -22.6%
2 analysts
MEAN TARGET
$478 +14.2%
17 analysts
HIGH TARGET
$685 +63.5%
22 analysts
PRICE RANGE
$324.00 - $685.00
SB / B / H / S / SS
13/16/10/1/1
DAILYIQ EST.
$508.68 (+21.5%)
Sector
Healthcare
Industry
Medical Instruments & Supplies
Exchange
NMS
Country
United States
Symbol
ISRG
Description
Intuitive Surgical is a medical technology company focused on advancing minimally invasive care through its innovative surgical systems. Its flagship product, the da Vinci Surgical System, allows surgeons to perform procedures with enhanced precision, offering a less invasive alternative to traditional surgery. Beyond surgery, Intuitive Surgical also offers the Ion endoluminal system, expanding its reach into diagnostic procedures, such as lung biopsies. The company's value proposition extends beyond its core products, providing comprehensive support through training programs, service and maintenance, and digital tools designed to optimize hospital performance. Intuitive Surgical distributes its products globally via direct sales teams, ensuring direct engagement with healthcare providers.
Bought (1Y)
0 shares
$0
Sold (1Y)
22,814 shares
$9.3M
WADORS PATRICIA LSVP Chief Human Resources Offi
Option Exercise2,140 shares2026-10-10
WADORS PATRICIA LSVP Chief Human Resources Offi
Tax Withholding1,062 shares2026-10-10
WADORS PATRICIA LSVP Chief Human Resources Offi
Option Exercise2,140 shares2026-10-10
LOEB GARYEVP & Chief Legal and Complian
Option Exercise2,612 shares2026-10-10
LOEB GARYEVP & Chief Legal and Complian
Tax Withholding1,296 shares2026-10-10
89/ 100
Strong bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
66.0%
Net Margin
28.4%
Revenue CAGR
17.0%
Current Ratio
4.87x
Return on Equity
16.0%
Earnings Summary
Intuitive Surgical, a leading medical technology firm, specializes in minimally invasive care through its da Vinci Surgical System and Ion endoluminal platform, delivering precision surgery worldwide. Operating in the high‑margin medical instruments sector, the company relies on a direct‑sales model that supports a robust recurring revenue stream from instrument sales and service contracts. In the most recent four quarters, ISRG’s earnings have shown a steady upward trajectory: Q4 2025 revenue rose to $2.866 billion, up 2.4 % from Q3 2025, while EPS climbed from $2.40 to $2.53, a 5.8 % increase. Q1 2026 revenue reached $2.771 billion, a 2.4 % rise over Q4 2025, and EPS edged to $2.50 from $2.53, a modest 1.2 % decline, yet still above analyst expectations. Across the last eight quarters, the company has consistently beat EPS estimates in six of eight periods, with revenue growth averaging 3.5 % YoY, underscoring a resilient top‑line even when EPS margins tighten. Recent news highlights a bullish consensus rating on Oct 8, citing strong market share and solid guidance, while analysts noted an 18 % revenue jump in Q2 2026 driven by recurring instrument sales and a 33.6 % operating margin that outpaces peers. The firm’s active integration of generative AI into product development, reported on Oct 5, positions it to capitalize on emerging digital tools in surgical care.

EPS

EstBeatMiss
$1.79$2.07$2.36$2.65$2.93Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.64 - -
Q2'26$2.55$2.80+9.8%
Q1'26$2.11$2.50+18.7%
Q4'25$2.30$2.53+9.8%
Q3'25$1.99$2.40+20.7%
Q2'25$1.92$2.19+14.1%

Revenue

EstBeatMiss
$2.4B$2.5B$2.7B$2.9B$3.0BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$3.0B - -
Q2'26$2.9B$2.9B+0.5%
Q1'26$2.6B$2.8B+5.8%
Q4'25$2.8B$2.9B+2.4%
Q3'25 - $2.5B -
Q2'25 - $2.4B -

Market Data

ISRG Stock Snapshot

BEARISH19/100
$418.82−$1.40 (0.3%)
Market cap
149.88B
P/E ratio
47.8
Day range
$414.65 – $425.50
News sentiment
65/100 · Bullish
Analyst target
$478.10 (+14.2%)
Consensus
Buy · 41 analysts
52-week range+27.5% off low · -30.6% from high
$328.57$603.88
Price $418.82 DailyIQ Est. $508.68

Price action on ISRG is defensive - rallies are being sold rather than extended. In Healthcare, names this size usually take direction from sector flows before company-level news.

Behaviour On Record

What ISRG's own history says about today's numbers

Realized volatility (21d)
26.0% 50th pct
Below its peak
-31.4%
vs 200-day average
-4.9%
Up days (1y)
48%

Intuitive Surgical, Inc. is currently running 26.0% annualised volatility over the last 21 sessions. Measured against ISRG's own 13 years of daily returns rather than a market-wide average, that is the 50th percentile — close to its own typical level, against a typical reading of 25.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

ISRG is trading -31.4% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -23.2%, and the deepest was -49.1% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -4.9% from its 200-day moving average. Against every other day in its history, that gap ranks at the 17th percentile — a narrower gap than it typically runs. Over the past year ISRG closed higher on 48% of sessions, and it is currently 2 sessions into a falling streak.

On October specifically: over 14 years of records, ISRG finished the month higher 9 of 14 times, with a median return of +4.5% and an average of +3.8%. Its strongest month historically has been November at +4.3% on average, its weakest March at -1.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: ISRG has opened more than 2% away from the prior close in 84 of 3,268 sessions (2.6% of the time), with the largest gaps running +5.4% and -9.2%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, ISRG moved an average of 4.6% in the session after earnings, closing higher 1 of those 3 times, with a median move of -2.8% and a largest of +7.1%.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against ISRG's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of ISRG's sector?

Intuitive Surgical, Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82

Options Market

What is the options market pricing for ISRG?

CallsPuts

For Intuitive Surgical, Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is roughly balanced between puts and calls (put/call ratio of 0.96), with at-the-money implied volatility around 40.9%. The options market is pricing roughly a ±3.7% move by that expiry — a range of about $411.64–$443.64.

Put/call ratio (2026-10-16)
0.96
ATM implied volatility
40.9%
Total open interest
19,719
Expected move by 2026-10-16
±3.7% ($411.64–$443.64)

Analyst Rating Changes

Are analysts turning bullish or bearish on ISRG?

BTIG most recently reiterated its rating on Intuitive Surgical, Inc. to Buy on Oct 12, 2026 with a price target of $454 (from $469). Over the last 90 days, coverage has run 1 upgrade against 1 downgrade, a net mixed lean.

Latest action
BTIG — Buy
90-day upgrades
1
90-day downgrades
1
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 12, 2026BTIGMaintainedBuy$469 → $454
Oct 7, 2026BarclaysInitiatedOverweight$485
Sep 8, 2026BTIGReiteratedBuy$469
Aug 12, 2026OppenheimerUpgradePerform → Outperform$500
Jul 30, 2026HSBCDowngradeBuy → Hold$931
Jul 17, 2026Raymond JamesMaintainedOutperform$577 → $483
Jul 17, 2026Piper SandlerReiteratedOverweight$580 → $470
Jul 17, 2026JP MorganMaintainedOverweight$550 → $450
Jul 17, 2026MizuhoMaintainedNeutral$500 → $400
Jul 17, 2026Wells FargoMaintainedOverweight$654 → $487
Jul 17, 2026TD CowenMaintainedBuy$520 → $485
Jul 17, 2026Evercore ISI GroupMaintainedIn-Line$430 → $375

Peers & ETF holders

ISRG peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

65/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Intuitive Surgical (ISRG) received a bullish earnings outlook upgrade from analysts, citing higher estimates, a robust recent quarter, and progress on gastrointestinal robotics projects in early regulatory review. The upgrade has drawn renewed investor attention, contributing to a 15.8% rise in the share price over the past month. While the year‑to‑date return remains negative, long‑term shareholders have benefited from a 56% total return over three years. The market reaction reflects confidence in ISRG’s growth prospects, though the upgrade is not deemed transformative.
What did this article say?
Intuitive Surgical (ISRG) announced it had submitted a next‑generation flexible robotic endoscope to the FDA for 510(k) clearance, targeting gastrointestinal care. The platform builds on the company’s existing da Vinci and Ion technologies but is still in early development and is not expected to generate revenue in the near term. Management highlighted collaboration with GI physicians to refine the system and indicated that the initiative represents a strategic expansion beyond traditional soft‑tissue surgery.
What did this article say?
Intuitive Surgical (ISRG) was upgraded to a Zacks Rank #2 (Buy) on October 13, reflecting a consensus view that earnings estimates are improving. The rating change signals that analysts expect stronger profitability in the near term, which could support a positive price move. The upgrade is based on consensus earnings projections and is considered a significant factor for investors evaluating the company’s valuation.
What did this article say?
The article identifies Intuitive Surgical (ISRG) as a compelling investment among sales‑growth stocks as the third‑quarter earnings season begins. It argues that consistent sales growth signals robust customer demand and effective market positioning, which can outweigh earnings volatility. By positioning ISRG alongside other high‑growth names, the piece suggests the company’s performance may attract investors seeking resilient business fundamentals amid macroeconomic uncertainty.
What did this article say?
Intuitive Surgical, Inc. (ISRG) closed its latest trading session at $423.96, up 2.06% from the previous day, outperforming the S&P 500 and the Nasdaq. The company’s shares had risen 15.24% over the month, while the medical sector fell 1.97% and the broader market gained 1.34%. Investors are anticipating the earnings announcement scheduled for October 20, 2026, with forecasts of $2.61 EPS and $2.88 billion revenue for the quarter, and year‑to‑date estimates of $10.74 EPS and $11.74 billion revenue. The data suggest a steady performance but no material catalyst to alter the company’s valuation trajectory.
What did this article say?
Leerink Partners raised its price target for Intuitive Surgical (ISRG) to $473 from $454, reflecting a bullish outlook on the company’s prospects. The firm maintains an overweight rating and cites a strong earnings trajectory and expanding market share in robotic surgery as key drivers. The adjustment signals confidence in ISRG’s ability to sustain growth and deliver shareholder value.
What did this article say?
Wall Street analysts have shifted their outlook on Intuitive Surgical (ISRG) toward a strong buy stance, with an average brokerage recommendation of 1.63 on a 1‑to‑5 scale. The majority of the 32 recommendations—22 strong buys and two buys—indicate a bullish view, translating to a 68.8% strong buy and 6.3% buy coverage. This consensus suggests growing confidence in ISRG’s product pipeline and market position, potentially supporting a higher valuation. Overall, the consensus signals a moderate‑to‑strong upside for ISRG based on current analyst coverage.
What did this article say?
In Q2 2026, ISRG reported 18% revenue growth and 85% of sales coming from recurring instrument sales, totaling $1.73 B. The company’s operating margin of 33.6% outpaced peers, reinforcing its premium valuation. While tariffs and a modest 2026 procedure growth guidance present risks, the early da Vinci 5 upgrade cycle and deferred surgeries mitigate downside concerns.
What did this article say?
Intuitive Surgical reported robust growth and high profitability, reinforcing its market leadership in robotic surgery. Technical analysis indicated a constructive setup that could precede a breakout rally. The company’s performance suggests continued demand for its surgical systems and software. These factors support a positive outlook for ISRG’s stock trajectory. The analysis was published on October 8.
What did this article say?
Barclays announced a bullish coverage initiation for Intuitive Surgical (ISRG) in early October 2026, highlighting the company as a high‑quality healthcare equipment firm amid a softer medical devices backdrop. The rating upgrade came as investors anticipated ISRG’s upcoming earnings release on October 20, expected to show year‑over‑year growth in earnings per share and revenue. Barclays emphasized ISRG’s strong balance sheet, healthy margins, and recurring revenue model while noting competitive pressure from Johnson & Johnson’s investment in rival robotic platforms. The positive initiation is expected to reinforce ISRG’s investment narrative and could influence market sentiment ahead of the earnings report.

Technical Analysis

Real-time indicators across multiple timeframes

19
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $64.19B combined position · 13 adding, 12 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy33,613,2989.43%$19.04B2026-01-29
BlackRock, Inc.▼ Sell30,024,6488.42%$11.94B2026-08-07
Invesco Ltd.▲ Buy11,843,5633.32%$4.71B2026-08-14
Geode Capital Management, LLC▲ Buy8,534,7672.39%$3.38B2026-08-12
Capital World Investors▼ Sell7,742,6812.17%$3.08B2026-08-12
Morgan Stanley▲ Buy6,561,3221.84%$2.61B2026-08-13
Norges Bank▼ Sell4,954,8741.39%$1.97B2026-08-12
JPMorgan Chase & Co▼ Sell4,231,0331.19%$1.72B2026-08-12
FMR LLC (Fidelity)▼ Sell4,251,1301.19%$1.69B2026-08-13
AllianceBernstein L.P.▼ Sell3,632,7661.02%$1.67B2026-08-14
Fisher Asset Management, LLC▲ Buy3,918,8401.10%$1.56B2026-08-04
Wellington Management Group LLP▼ Sell3,802,0031.07%$1.51B2026-08-14
Northern Trust Corp▲ Buy3,512,9960.99%$1.40B2026-08-13
Bank of America Corp▼ Sell3,403,7590.95%$1.35B2026-08-14
Goldman Sachs Group Inc▲ Buy2,891,8770.81%$1.15B2026-08-14
Baillie Gifford & Co▼ Sell2,524,4270.71%$1.00B2026-08-06
Two Sigma Investments, LP▲ Buy1,979,1280.56%$787.06M2026-08-14
Janus Henderson Group plc▲ Buy1,643,0600.46%$757.49M2026-05-18
Loomis Sayles & Co L P▼ Sell1,656,1560.46%$658.62M2026-08-14
Capital Research Global Investors▲ Buy1,551,6640.44%$617.07M2026-08-12
Wells Fargo & Company▼ Sell1,027,5420.29%$408.63M2026-08-14
Citigroup Inc▲ Buy834,6670.23%$331.93M2026-08-03
Coatue Management LLC▼ Sell793,7040.22%$315.64M2026-08-14
Squarepoint Ops LLC▲ Buy745,1890.21%$296.35M2026-08-14
D1 Capital Partners L.P.▲ New574,2000.16%$228.35M2026-08-14
Q2 2026 flow:7.92M sh bought ($3.15B)2.75M sh sold ($1.11B)net +5.17M sh (+$2.04B)
Congressional Trading Activity
24 disclosed trades · ~$265.5K est. traded value · 10 buys, 14 sells
MemberChamberStateTypeAmountTradedFiled
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-01-302026-02-13
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-12-102026-01-12
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-11-182025-12-15
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2025-09-032025-10-15
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-07-162025-08-13
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-07-102025-08-13
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-06-092025-08-13
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-05-082025-06-22
Bruce WestermanHouseAR04▼ Sell$1K - $15K2025-04-212025-05-12
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2025-04-092025-05-14
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-04-072025-05-14
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-04-072025-05-08
Bruce WestermanHouseAR04▲ Buy$1K - $15K2025-03-032025-04-16
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-01-302025-02-11
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2025-01-292025-02-10
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2025-01-212025-02-10
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2024-12-232025-01-14
Lisa McClainHouseMI09▲ Buy$1K - $15K2024-12-112025-08-13
John F. ReedSenateRI▼ Sell$1K - $15K2019-02-282019-03-18
John F. ReedSenateRI▼ Sell$1K - $15K2019-02-042019-03-01
John F. ReedSenateRI▼ Sell$1K - $15K2018-03-092018-03-12
John F. ReedSenateRI▲ Buy$1K - $15K2016-11-232016-11-28